Resveratrol for Exudative Age-Related Macular Degeneration
NCT ID: NCT02625376
Last Updated: 2020-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
25 participants
INTERVENTIONAL
2015-08-06
2016-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxidative Stress in Patients With Age-Related Macular Degeneration
NCT00465400
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
NCT01528605
The Influence of Lutein Supplements on Age-related Macular Degeneration
NCT01042860
A Study to Evaluate the Safety and Efficacy of RQC for AMD
NCT05062486
Role of Xanthophylls in Visual Function
NCT05794074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Comparison of incidence of choroidal neaovascularization between each study group will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trans-Resveratrol
capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
Trans-Resveratrol
Dietary supplementation with resveratrol 250 mg BD
Resvega
capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.
two capsules daily : one in the morning and evening for 24 months
Resvega
Dietary supplementation with Resvega BD
Placebo
capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
placebo
Dietary supplementation with a placebo BD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resvega
Dietary supplementation with Resvega BD
Trans-Resveratrol
Dietary supplementation with resveratrol 250 mg BD
placebo
Dietary supplementation with a placebo BD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual acuity less or equal to 20/25 in the most affected eye
Exclusion Criteria
* atrophic Age-Related Macular Degeneration or age related maculopathy
* significant media opacities
* Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy)
* Recent Cataract surgery
* Previous history of vitrectomy
* Acute or chronic severe organ failure
* Present participation in other clinical research study
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas LEVEZIEL, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dpt of Ophthalmology, University Hospital of Poitiers, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Poitiers - Ophtalmology
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGED/EudraCT : 2015-001577-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.